PDF herunterladen
Thromb Haemost 1999; 82(06): 1568-1577
DOI: 10.1055/s-0037-1614880
Review Article
Schattauer GmbH

Biologic Activities of the Contact Factors In Vivo

Potentiation of Hypotension, Inflammation, and Fibrinolysis, and Inhibition of Cell Adhesion, Angiogenesis and Thrombosis
Robert W. Colman
1   From the Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA, USA
› InstitutsangabenThis review was partially supported by grants from NIH, P01 HL56914 and CA 83121. I thank Rita Stewart for expert manuscript preparation and for executing the figures.
Weitere Informationen

Publikationsverlauf

Received 13. Juli 1999

Accepted after revision 02. September 1999

Publikationsdatum:
10. Dezember 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

 

 

  • References

  • 1 Lin Y, Harris RB, Yan W, McCrae KR, Zhang H, Colman RW. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood 1997; 90: 690-7.
    PubMedGoogle Scholar
  • 2 Motta G, Rojkjaer R, Hasan AAK, Cines DB, Schmaier AH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells – a novel mechanism for contact activation. Blood 1998; 91: 516-28.
    PubMedGoogle Scholar
  • 3 Rojkjaer R, Hasan AA, Motta G, Schousboe I, Schmaier AH. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 1998; 80 (01) 74-81.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 4 Rojkjaer R, Schmaier AH. Activation of the plasma kallikrein/kinin system on endothelial cells. Proc Assoc Am Physicians 1999; 111 (03) 220-7.
    CrossrefPubMedGoogle Scholar
  • 5 Kurachi K, Fujikawa K, Davie EW. Mechanism of activation of bovine factor XI by factor XII and factor XIIa. Biochemistry 1980; 19: 1330-8.
    CrossrefPubMedGoogle Scholar
  • 6 Radcliffe R, Bagdasarian A, Colman R, Nemerson Y. Activation of bovine factor VII by Hageman factor fragments. Blood 1977; 50: 611-7.
    PubMedGoogle Scholar
  • 7 Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 1983; 71: 1450-6.
    CrossrefPubMedGoogle Scholar
  • 8 Hauert J, Bachmann F. Prourokinase activation in euglobulin fractions. Thromb.Haemost 1985; 54: 122-7.
    PubMedGoogle Scholar
  • 9 Ichinose A, Fujikawa K, Suyama T. The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J. Biol. Chem. 1986; 261: 3486-9.
    PubMedGoogle Scholar
  • 10 Sealey JE, Atlas SA, Laragh JH. Linking the kallikrein and renin systems via activation of inactive renin: new data and a hypothesis. Am J Med 1978; 65: 994-1000.
    CrossrefPubMedGoogle Scholar
  • 11 Sealey JE, Atlas SA, Laragh JH, Silverberg M, Kaplan AP. Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein. Proc Natl Acad Sci USA 1979; 76: 5914-8.
    CrossrefPubMedGoogle Scholar
  • 12 Fujikawa K, Heimark RL, Kurachi K, Davie EW. Activation of bovine factor XII (Hageman factor) by plasma kallikrein. Biochemistry 1980; 19: 1322-30.
    CrossrefPubMedGoogle Scholar
  • 13 Jacobsen S, Kriz M. Some data on two purified kininogens from human plasma. Br. J. Pharmacol 1967; 29: 25-36.
    PubMedGoogle Scholar
  • 14 Chien P, Pixley RA, Stumpo LG, Colman RW, Schreiber AD. Modulation of the human monocyte binding site for monomeric immunoglobulin G by activated Hageman factor. J Clin Invest 1988; 82: 1554-9.
    CrossrefPubMedGoogle Scholar
  • 15 Toossi Z, Sedor JR, Mettler MA, Everson B, Young T, Ratnoff OD. Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII). Proc Natl Acad Sci USA 1992; 89: 11969-72.
    CrossrefPubMedGoogle Scholar
  • 16 Wachtfogel YT, Pixley RA, Kucich U, Abrams W, Weinbaum G, Schapira M, Colman RW. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 1986; 67: 1731-7.
    PubMedGoogle Scholar
  • 17 Schapira M, Despland E, Scott CF, Boxer LA, Colman RW. Purified human plasma kallikrein aggregates human blood neutrophils. J Clin Invest 1982; 69: 1199-202.
    CrossrefPubMedGoogle Scholar
  • 18 Yung LL, Colman RW, Cooper SL. Neutrophil adhesion on polymethanes preadsorbed with high molecular weight kininogen. Blood 1999; 94: 2716-24.
    PubMedGoogle Scholar
  • 19 Puri RN, Zhou F, Hu CJ, Colman RF, Colman RW. High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets. Blood 1991; 77: 500-7.
    PubMedGoogle Scholar
  • 20 Colman RW, Schmaier AH. Contact system: A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-43.
    PubMedGoogle Scholar
  • 21 Hong SL. Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein. Thromb Res 1980; 18: 787-95.
    CrossrefPubMedGoogle Scholar
  • 22 Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biologic activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
    CrossrefPubMedGoogle Scholar
  • 23 Boulanger C, Schini VB, Moncada S, Vanhoutte PM. Stimulation of cyclic GMP production in cultured endothelial cells of the pig by bradykinin, adenosine diphosphate, calcium ionophore A23187 and nitric oxide. Br J Pharmacol 1990; 101: 152-6.
    CrossrefPubMedGoogle Scholar
  • 24 Schini VB, Boulanger C, Regoli D, Vanhoutte PM. Bradykinin stimulates the production of cyclic GMP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells. J Pharmacol Exp Ther 1990; 252: 581-5.
    PubMedGoogle Scholar
  • 25 Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 1990; 275: 87-90.
    CrossrefPubMedGoogle Scholar
  • 26 Imai T, Hirata Y, Kanno K, Marumo F. Induction of nitric oxide synthase by cyclic AMP in rat vascular smooth muscle cells. J Clin Invest 1994; 93: 543-9.
    CrossrefPubMedGoogle Scholar
  • 27 Dixon BS, Breckon R, Fortune J, Vavrek RJ, Stewart JM, Marzec-Calvert R, Linas SL. Effects of kinins on cultured arterial smooth muscle. Am J Physiol 1990; 258: C299-C308.
    CrossrefPubMedGoogle Scholar
  • 28 Dixon BS, Sharma RV, Dickerson T, Fortune J. Bradykinin and angiotensin II: activation of protein kinase C in arterial smooth muscle. Am J Physiol 1994; 266: C1406-C20.
    CrossrefPubMedGoogle Scholar
  • 29 McEachern AE, Shelton ER, Bhakta S, Obernolte R, Bach C, Zuppan P, Fujisaki J, Aldrich RW, Jarnagin K. Expression cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci USA 1991; 88: 7724-8.
    CrossrefPubMedGoogle Scholar
  • 30 Menke JG, Borkowski JA, Bierilo K, MacNeil T, Derrick AM, Schneck KA, Ransom RW, Strader CD, Linemayer DL, Hess JF. Expression cloning of a human B1 bradykinin receptor. J Biol Chem 1994; 269: 21583.
    PubMedGoogle Scholar
  • 31 Linz W, Scholkens BA. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992; 20 (Suppl. 09) S83.
    PubMedGoogle Scholar
  • 32 Gohlke P, Linz W, Scholkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension 1994; 23: 411.
    PubMedGoogle Scholar
  • 33 O’Sullivan JB, Harrap SB. Resetting blood pressure in spontaneously hypertensive rats. The role of bradykinin. Hypertension 1995; 25: 162.
    PubMedGoogle Scholar
  • 34 Borkowski JA, Hess JF. Targeted disruption of the mouse B2 bradykinin receptor in embryonic stem cells. Canadian Journal of Physiology & Pharmacology 1995; 73 (07) 773-9.
    CrossrefPubMedGoogle Scholar
  • 35 Alfie ME, Yang XP, Hess F, Carretero OA. Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochemical & Biophysical Research Communications 1996; 224 (03) 625-30.
    CrossrefPubMedGoogle Scholar
  • 36 Alfie ME, Sigmon DH, Pomposiello SI, Carretero OA. Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension 1997; 29 (01) (Suppl. 02) 483-7.
    CrossrefPubMedGoogle Scholar
  • 37 Emanueli C, Angioni GR, Anania V, Spissu A, Madeddu P. Blood pressure responses to acute or chronic captopril in mice with disruption of bradykinin B2-receptor gene. Journal of Hypertension 1997; 15 (12) (Suppl. 02) 1701-6.
    CrossrefPubMedGoogle Scholar
  • 38 Madeddu P, Milia AF, Salis MB, Gaspa L, Gross W, Lippoldt A, Emanueli C. Renovascular hypertension in bradykinin B2-receptor knockout mice. Hypertension 1998; 32 (03) 503-9.
    CrossrefPubMedGoogle Scholar
  • 39 Yang XP, Liu YH, Scicli GM, Webb CR, Carretero OA. Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension 1997; 30 (03) (Suppl. 02) 735-40.
    CrossrefPubMedGoogle Scholar
  • 40 Siebeck J, Cheronis JC, Fink E, Kohl J, Spies B, Spannagl M, Jochum M, Fritz H. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J Appl Physiol 1994; 77: 2675.
    CrossrefPubMedGoogle Scholar
  • 41 Ma JX, Yang Z, Chao J, Chao L. Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein. J Biol Chem 1995; 270: 451-5.
    CrossrefPubMedGoogle Scholar
  • 42 Wang C, Chao L, Chao J. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 1995; 95: 1710-6.
    CrossrefPubMedGoogle Scholar
  • 43 Xiong W, Chao J, Chao L. Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension 1995; 25: 715-9.
    CrossrefPubMedGoogle Scholar
  • 44 Bone R. Sepsis and multiple organ failure: Consensus and controversy. In: Lamy M, Thijs LG. eds. Mediators of Sepsis. New York: Springer-Verlag; 1992: 3-12.
    Google Scholar
  • 45 Waage A, Brandtzaeg P, Halstensen A. The complex patterns of cytokines in serum from patients with meningococcal septic shock: Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989; 169: 333.
    CrossrefPubMedGoogle Scholar
  • 46 Beutler B, Cerami A. Cachectin: More than a tumor necrosis factor. N Engl J Med 1987; 316: 379-85.
    CrossrefPubMedGoogle Scholar
  • 47 Carmona RH, Tsao TC, Trunkey DD. The role of prostacyclin and thromboxane in sepsis and septic shock. Arch Surg 1984; 119: 189-92.
    CrossrefPubMedGoogle Scholar
  • 48 Philippe J, Dooijewaard G, Offner F, Turion P, Baele G, Leroux-Roels G. Granulocyte elastase, tumor necrosis factor-a and urokinase levels as prognostic markers in severe infection. Thromb Haemost 1992; 68: 19-23.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 49 Smith-Erichsen N, Aasen AO, Gallimore MJ, Amundsen E. Studies of components of the coagulation systems in normal individuals and septic shock patients. Circ Shock 1982; 9: 491-7.
    PubMedGoogle Scholar
  • 50 Voss R, Borkowski G, Reitz D, Ditter H, Matthias FR. Endogenous fibrinolysis in septic patients. Second Vienna Shock Forum 1989; 383-7.
    PubMedGoogle Scholar
  • 51 Kalter ES, Daha MR, Verhoef J, Bouma BN. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 1985; 151: 1019-27.
    CrossrefPubMedGoogle Scholar
  • 52 Colman RW. The role of plasma proteases in septic shock. N Engl J Med 1989; 320: 1207-9.
    CrossrefPubMedGoogle Scholar
  • 53 Chhibber G, Cohen A, Lane S, Farber A, Meloni FJ, Schmaier AH. Immunoblotting of plasma in a pregnant patient with hereditary angioedema. J Lab Clin Med 1990; 115: 112-21.
    PubMedGoogle Scholar
  • 54 Carvalho AC, DeMarinis S, Scott CF, Silver LD, Schmaier AH, Colman RW. Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. J Lab Clin Med 1988; 112: 270-7.
    PubMedGoogle Scholar
  • 55 Mason JW, Colman RW. The role of Hageman factor in disseminated intravascular coagulation induced by septicemia, neoplasia, or liver disease. Thromb Diath Haemorrh 1971; 26: 325-31.
    PubMedGoogle Scholar
  • 56 O'Donnell TF, Clowes GH, Talamo RC, Colman RW. Kinin activation in the blood of patients with sepsis. Surg Gynecol Obstet 1976; 143: 539-45.
    PubMedGoogle Scholar
  • 57 Colman RW, Edelman R, Scott CF, Gilman RH. Plasma kallikrein activation and inhibition during typhoid fever. J Clin Invest 1978; 61: 287-96.
    CrossrefPubMedGoogle Scholar
  • 58 Rao AK, Schapira M, Clements ML, Niewiarowski S, Budzynski AZ, Schmaier AH, Harpel PC, Blackwelder WC, Scherrer JR, Sobel E, Colman RW. A prospective study of platelets and plasma proteolytic systems during the early stages of Rocky Mountain spotted fever. N Engl J Med 1988; 318: 1021-8.
    CrossrefPubMedGoogle Scholar
  • 59 Nuijens JH, Huijbregts CC, Eerenberg Belmer AJ, Abbink JJ, Strack van Schijndel RJ, Felt Bersma RJ, Thijs LG, Hack CE. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. Blood 1988; 72: 1841-8.
    PubMedGoogle Scholar
  • 60 Kaufman N, Page JD, Pixley RA, Schein R, Schmaier AH, Colman RW. Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 1991; 77: 2660-7.
    PubMedGoogle Scholar
  • 61 DeLa Cadena RA, Suffredini AF, Page JD, Pixley RA, Kaufman N, Parrillo JE, Colman RW. Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers. Blood 1993; 81: 3313-7.
    PubMedGoogle Scholar
  • 62 Pixley RA, DeLa Cadena RA, Page JD, Kaufman N, Wyshock EG, Colman RW, Chang A, Taylor Jr. FB. Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am.J.Pathol 1992; 140: 897-906.
    PubMedGoogle Scholar
  • 63 Pixley RA, DeLa Cadena RA, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor Jr. FB, Colman RW. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91: 61-8.
    CrossrefPubMedGoogle Scholar
  • 64 DeLa Cadena RA, Laskin KJ, Pixley RA, Sartor RB, Schwab JH, Back N, Bedi GS, Fisher RS, Colman RW. Role of kallikrein-kinin system in pathogenesis of bacterial cell wall-induced inflammation. A J Physiol 1991; 260: G213-G9.
    PubMedGoogle Scholar
  • 65 DeLa Cadena RA, Stadnicki A, Uknis AB, Sartor RB, Kettner CA, Adam A, Colman RW. Inhibition of plasma kallikrein prevents peptidoglycan-induced arthritis in the Lewis rat. FASEB J 1995; 9: 446-52.
    CrossrefPubMedGoogle Scholar
  • 66 Blais Jr. C, Couture R, Drapeau G, Colman RW, Adam AA. Involvement of endogenous kinins in the pathogenesis of peptidoglycan-induced arthritis in the Lewis rat. Arthritis Rheum 1997; 40: 1327-33.
    CrossrefPubMedGoogle Scholar
  • 67 Sartor RB, DeLa Cadena RA, Green KD, Stadnicki A, Davis SW, Schwab JH, Adam AA, Raymond P, Colman RW. Selective kallikreinkinin system activation in inbred rats differentially susceptible to granulomatous enterocolitis. Gastroenterology 1996; 110: 1467-81.
    CrossrefPubMedGoogle Scholar
  • 68 Stadnicki A, DeLa Cadena RA, Sartor RB, Bender D, Kettner CA, Rath HC, Adam A, Colman RW. Selective plasma kallikrein inhibitor attenuates acute intestinal inflammation in Lewis rat. Dig Dis Sci 1996; 41: 912-20.
    CrossrefPubMedGoogle Scholar
  • 69 Stadnicki A, Sartor RB, Janardham R, Majluf-Cruz A, Kettner C, Adam AA, Colman RW. Specific inhibition of plasma kallikrein modulates chronic granulomatous intestinal and systemic inflammation in genetically susceptible rats. FASEB J 1998; 12: 325-33.
    CrossrefPubMedGoogle Scholar
  • 70 Jansen PM, Pixley RA, Brouwer M, DeJong IW, Chang AK, Hack CE, Taylor Jr. FB, Colman RW. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996; 87: 2337-44.
    CrossrefPubMedGoogle Scholar
  • 71 Colman RW, Scott CF, Pixley RA, DeLa Cadena RA. Effect of heparin on the inhibition of the contact system enzymes. Ann.NY.Acad.Sci 1989; 556: 95-103.
    CrossrefPubMedGoogle Scholar
  • 72 Wachtfogel YT, Harpel PC, Edmunds Jr. LH, Colman RW. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood. 1989; 73: 468-71.
    PubMedGoogle Scholar
  • 73 Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, Edmunds Jr. LH. Aprotinin inhibits the contact, neutrophil and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106: 1-10.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 74 Wachtfogel YT, Hack CE, Nuijens JH, Kettner C, Reilly TM, Knabb RM, Bischoff R, Tschesche H, Wenzel H, Kucich U, Edmunds Jr. LH, Colman RW. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am J Physiol 1995; 268: H1352-H7.
    PubMedGoogle Scholar
  • 75 Colman RW, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimaraes JA, Pierce JV, Kaplan AP. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 1975; 56: 1650-62.
    PubMedGoogle Scholar
  • 76 Colman RW. Activation of plasminogen by human plasma kallikrein. Biochem. Biophys Res Commun 1969; 35: 273-9.
    CrossrefPubMedGoogle Scholar
  • 77 Mandle Jr. RJ, Kaplan AP. Human plasma prekallikrein: Mechanism of activation by Hageman factor and participation in Hageman-factor-dependent fibrinolysis. J Biol Chem 1977; 252: 6097-104.
    PubMedGoogle Scholar
  • 78 Loza JP, Gurewich V, Johnstone M, Pannell R. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb Haemost 1994; 71: 347-52.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 79 Gurewich V, Johnstone M, Loza JP, Pannell R. Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEBS Lett 1993; 318: 317-21.
    CrossrefPubMedGoogle Scholar
  • 80 Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang J, Mazar A, McCrae KR. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2+3 of the urokinase receptor. J Clin Invest 1997; 100: 1481-7.
    CrossrefPubMedGoogle Scholar
  • 81 Zini JM, Schmaier AH, Cines DB. Bradykinin regulates the expression of kininogen binding sites on endothelial cells. Blood 1993; 81: 2936-46.
    PubMedGoogle Scholar
  • 82 Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1983; 66: 835-9.
    PubMedGoogle Scholar
  • 83 Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77 (03) 522-5.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 84 Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999; 33 (06) 1431-5.
    CrossrefPubMedGoogle Scholar
  • 85 Higazi A, Cohen RL, Henkin J, Kniss D, Schwartz BS, Cines DB. Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor. J Biol Chem 1995; 21: 17375-80.
    PubMedGoogle Scholar
  • 86 Vroman L, Adams A. Possible involvement of fibrinogen and proteolysis in surface activation: A study with the recording ellipsometer. Thromb Diath Haemorrh 1967; 18: 510-24.
    PubMedGoogle Scholar
  • 87 Schmaier AH, Silver L, Adams AL, Fischer GC, Munoz PC, Vroman L, Colman RW. The effect of high molecular weight kininogen on surface-adsorbed fibrinogen. Thromb Res 1984; 33: 51-67.
    CrossrefPubMedGoogle Scholar
  • 88 Brash JL, Scott CF, ten Hove P, Wojciechowski P, Colman RW. Mechanism of transient adsorption of fibrinogen from plasma to solid surfaces: role of the contact and fibrinolytic systems. Blood 1988; 71: 932-9.
    PubMedGoogle Scholar
  • 89 Scott CF, Silver LD, Purdon AD, Colman RW. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. J Biol Chem 1985; 260: 10856-63.
    PubMedGoogle Scholar
  • 90 Kunapuli SP, DeLa Cadena RA, Colman RW. Deletion mutagenesis of high molecular weight kininogen light chain: Identification of two anionic surface binding subdomains. J Biol Chem 1993; 268: 2486-92.
    PubMedGoogle Scholar
  • 91 DeLa Cadena RA, Colman RW. The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface. Prot Sci 1992; 1: 151-60.
    PubMedGoogle Scholar
  • 92 Bjork I, Olson ST, Sheffer RG, Shore JD. Binding of heparin to human high molecular weight kininogen. Biochemistry 1989; 28: 1213-21.
    CrossrefPubMedGoogle Scholar
  • 93 Gustafson EJ, Lukasiewicz H, Wachtfogel YT, Norton KJ, Schmaier AH, Niewiarowski S, Colman RW. High molecular weight kininogen inhibits fibrinogen binding to cytoadhesins of neutrophils and platelets. J Cell Biol 1989; 109: 377-87.
    CrossrefPubMedGoogle Scholar
  • 94 Asakura S, Hurley RW, Skorstengaard K, Ohkubo I, Mosher DF. Inhibition of cell adhesion by high molecular weight kininogen. J Cell Biol 1992; 116: 465-76.
    CrossrefPubMedGoogle Scholar
  • 95 Colman RW, Jameson B, Lin Y, Johnson D, Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) downregulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood. 1999 in press.
    PubMedGoogle Scholar
  • 96 Schmaier AH, Bradford HN, Lundberg D, Farber A, Colman RW. Membrane expression of platelet calpain. Blood 1990; 75: 1273-81.
    PubMedGoogle Scholar
  • 97 Saido T, Suzuki H, Yamazaki H, Tanoue K, Suzuki K. In situ capture of m-calpain activation of platelets. J Biol Chem 1993; 268: 7422-6.
    PubMedGoogle Scholar
  • 98 Puri RN, Zhou FX, Bradford H, Hu CJ, Colman RF, Colman RW. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain. Arch Biochem Biophys 1989; 271: 346-58.
    CrossrefPubMedGoogle Scholar
  • 99 Puri RN, Zhou FX, Colman RF, Colman RW. Cleavage of a 100 kDa membrane protein (aggregin) during thrombin-induced platelet aggregation is mediated by the high affinity thrombin receptors. Biochem Biophys Res Commun 1989; 162: 1017-24.
    CrossrefPubMedGoogle Scholar
  • 100 Puri RN, Matsueda R, Umeyama H, Bradford HN, Colman RW. Modulation of thrombin-induced platelet aggregation by inhibition of calpain by a synthetic peptide derived from the thiol-protease inhibitory sequence of kininogens and S-(3-nitro-2-pyridinesulfenyl)-cysteine. Biochem Biophys Res Commun 1989; 162: 1017-24.
    CrossrefPubMedGoogle Scholar
  • 101 Matsueda R, Umeyama H, Puri RN, Bradford HN, Colman RW. Design and synthesis of a kininogen-based selective inhibitor of thrombin-induced platelet aggregation. Pept Res 1994; 7: 32-5.
    PubMedGoogle Scholar
  • 102 Jiang YP, Muller Esterl W, Schmaier AH. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. J Biol Chem 1992; 267: 3712-7.
    PubMedGoogle Scholar
  • 103 Charo IF, Feinman RD, Detwiler TC. Interrelations of platelet aggregation and secretion. J Clin Invest 1977; 60: 866-73.
    CrossrefPubMedGoogle Scholar
  • 104 Kunapuli SP, Bradford HN, Jameson BA, DeLa Cadena RA, Rick L, Wassell RP, Colman RW. Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 domain 3 in the heavy chain of high molecular weight kininogen. J Biol Chem 1996; 271: 11228-34.
    CrossrefPubMedGoogle Scholar
  • 105 Bradford HN, DeLa Cadena RA, Kunapuli SP, Dong JF, Lopez JA, Colman RW. Human kininogens regulate thrombin binding to platelets through the GPIb-IX-V complex. Blood 1997; 90: 1508-15.
    PubMedGoogle Scholar
  • 106 Hasan AAK, Amenta S, Schmaier AH. Bradykinin and its metabolite, Arg-Pro-Pro-Gly-Phe, are selective inhibitors of α-thrombin-induced platelet activation. Circulation 1996; 94: 517-28.
    CrossrefPubMedGoogle Scholar
  • 107 Majima M, Sunahara N, Harada Y, Katori M. Detection of the degradation products of bradykinin by enzyme immunoassays as markers for the release of kinin in vivo. Biochem Pharmacol 1993; 45: 559-67.
    CrossrefPubMedGoogle Scholar
  • 108 Shima C, Majima M, Katori M. A stable metabolite, Arg-Pro-Pro-Gly-Phe, of bradykinin in the degradation pathway in human plasma. Jpn J Pharmacol 1992; 60: 111-9.
    CrossrefPubMedGoogle Scholar
  • 109 Margolius Jr. A, Ratnoff OD. Observations on the hereditary nature of Hageman trait. Blood 1956; 11: 565.
    PubMedGoogle Scholar
  • 110 White CA, Rees TD, Hurt WC. Factor XII (Hageman factor) deficiency in a periodontal surgery patient. J Oral Med 1986; 41: 105.
    PubMedGoogle Scholar
  • 111 Ratnoff OD, Busse Jr. RJ, Sheon RP. The demise of John Hageman. N Engl J Med 1968; 279: 760.
    CrossrefPubMedGoogle Scholar
  • 112 Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore) 1983; 62: 248-55.
    CrossrefPubMedGoogle Scholar
  • 113 Mannhalter C, Fisher M, Hopmeier P, Deutch E. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis 1987; 1: 259-63.
    PubMedGoogle Scholar
  • 114 Lammle B, Wuillemin WA, Huber I, Krauskopf M, Zurcher C, Pflugshaupt R, Furlan M. Thromboembolism and bleeding tendency in congenital factor XII deficiency: A study on 74 subjects from 14 Swiss families. Thromb Haemost 1991; 65: 117-21.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 115 Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost 1992; 68: 285-90.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 116 von Kanel R, Wuillemin WA, Furlan M, Lammle B. Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagul Fibrinolysis 1992; 3: 555-61.
    CrossrefPubMedGoogle Scholar
  • 117 Jespersen J, Munkvad S, Pedersen OD, Gram J, Kluft C. Evidence for a role of factor XII-dependent fibrinolysis in cardiovascular diseases. Ann N Y Acad Sci 1992; 667: 454-6.
    CrossrefPubMedGoogle Scholar
  • 118 Munkvad S, Jespersen J, Gram J, Kluft C. Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study. J Am Coll Cardiol 1991; 17: 957-62.
    CrossrefPubMedGoogle Scholar
  • 119 Hattersley WE, Hayse D. Fletcher factor deficiency: A report of three unrelated cases. Br Haematol 1970; 18: 411-5.
    CrossrefPubMedGoogle Scholar
  • 120 Currimbhoy Z, Vinciguerra V, Palakavongs P, Kuslansky P, Degnan TJ. Fletcher factor deficiency and myocardial infarction. Am J Clin Pathol 1976; 65: 970.
    CrossrefPubMedGoogle Scholar
  • 121 Harris MG, Exner T, Rickard KA, Kronenberg H. Multiple cerebral thrombosis in Fletcher factor (prekallikrein) deficiency: A case report. Am J Hematol 1985; 19: 387.
    CrossrefPubMedGoogle Scholar
  • 122 Saito H, Ratnoff OD, Donaldson VH. Defective activation of clotting, fibrinolysis and performance-enhancing systems in human Fletcher trait plasma. CircRes 1974; 34: 641.
    PubMedGoogle Scholar
  • 123 Donaldson VH, Glueck HI, Miller MA, Movat HZ, Habal F. Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in clotting and fibrinolysis. J Lab Clin Med 1976; 87: 327-37.
    PubMedGoogle Scholar
  • 124 Wuepper KD, Miller DR, Lacombe MJ. Flaujeac trait. Deficiency of human plasma kininogen. J Clin Invest 1975; 56: 1663-72.
    CrossrefPubMedGoogle Scholar
  • 125 Damas J, Adam A. The kallikrein-kininogen-kinin system in the Brown Norway rat. Biomedicine 1979; 31: 249.
    PubMedGoogle Scholar
  • 126 Hayashi I, Hoshiko S, Makabe O, Oh-ishi S. A point mutation of alanine 163 to threonine is responsible for the defective secretion of high molecular weight kininogen by the liver of brown Norway Katholiek rats. J Biol Chem 1993; 268: 17219-24.
    PubMedGoogle Scholar
  • 127 Colman RW, White JV, Scovell S, Stadnicki A, Sartor RB. Kininogens are antithrombotic proteins in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 2245-50.
    CrossrefPubMedGoogle Scholar